|
Patent landscape, scope, and claims: |
US Patent 9,388,134 scope, claims, and US patent landscape for trisodium[3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate]hemipentahydrate
The patent is a method-of-treatment patent that is tightly anchored to a single active ingredient: a defined trisodium hemipentahydrate salt form of a complex stereodefined biphenyl-containing compound. The claim set layers (i) indication scope (heart failure and hypertension), (ii) formulation/dosage-form delivery (pharmaceutical composition), and (iii) progressively narrower solid-state identity controls using ATR-FTIR and X-ray powder diffraction (XRPD) signatures plus crystallographic parameters for a specific monoclinic polymorph/solvate. In practice, this structure creates an exclusivity “funnel”: broad therapeutic coverage at Claim 1, then narrower infringement triggers when the infringing product is outside the specific solid-state fingerprints claimed in dependent claims 5 to 15.
Because only the claim text is provided, this analysis maps claim scope and likely infringement architecture across the US patent landscape, but does not reproduce bibliographic data (assignee, filing/grant/expiration dates, prosecution history) or connect to Orange Book listings or specific generic/Paragraph IV cases, which cannot be derived from the provided claim excerpt alone.
What does US Patent 9,388,134 claim protect: the method-of-treatment or the specific solid form?
Featured-snippet answer
It protects a method of treating heart failure or hypertension by administering a therapeutically effective amount of the specific trisodium hemipentahydrate crystalline compound, with dependent claims tightening protection to pharmaceutical compositions and then to particular crystalline identity features proven by ATR-FTIR and XRPD and specified crystallography.
Claim architecture overview
- Claim 1 (core method claim, broadest): treatment of a cardiovascular condition or disease (heart failure or hypertension) in a patient, with administration of the therapeutically effective amount of the exact named compound in the hemipentahydrate form.
- Claims 2–3 (indication narrowing): chronic heart failure; hypertension.
- Claim 4 (delivery/containment narrowing): administration “in the form of a pharmaceutical composition.”
- Claims 5–15 (solid-state identity narrowing): the compound must be in the crystalline form and must meet specified ATR-FTIR absorption bands and XRPD peak patterns, and must align with defined crystallography (monoclinic, space group P2i, unit cell parameters, Z, densities, and asymmetric unit content) plus selected XRPD peak subsets.
How broad is claim 1: what patient populations and cardiovascular conditions are covered?
Indication scope is limited to cardiovascular endpoints
Claim 1 is confined to:
- Heart failure (not otherwise specified at Claim 1, then narrowed at Claim 2 to chronic heart failure)
- Hypertension (Claim 3 narrows nothing further)
There is no explicit coverage for comorbidities, related cardiovascular syndromes, or other diseases in the excerpt.
Patient “in need thereof” is a standard limitation
The claim uses “in a patient in need thereof,” which typically captures both newly diagnosed and established patients where a clinician would consider the drug appropriate. The practical scope is therefore tied to the same clinical indication the drug is marketed/dispensed for.
Key scope lever: administration of the exact named salt solvate
Even if a generic develops a compound that is pharmacologically similar, infringement on Claim 1 requires the exact compound identity as written:
- trisodium
- stereodefined structure
- hemipentahydrate
- named stereochemical descriptors: (1S,3R) and (S) and “3′-methyl”
- tetrazolyl biphenyl side groups as specified
When does dependent claim 4 matter: does it require a particular dosage form?
Claim 4 requires “pharmaceutical composition” delivery
Claim 4 adds a containment limitation: the compound is administered “in the form of a pharmaceutical composition.” This typically covers tablets, capsules, powders, granulates, and suspensions, as long as they are pharmaceutical compositions containing the claimed active ingredient.
From an infringement perspective:
- If a competitor supplies the active as a bulk API and a third party formulates, Claim 4 may be harder to assert unless the accused product is a pharmaceutical composition “administered” to the patient.
- Claim 1 still remains a method-of-treatment claim that can be implicated even without specifying dosage form, because Claim 1 already requires “administering” the therapeutically effective amount.
Which patents protect crystalline solid forms: how do ATR-FTIR and XRPD features narrow infringement in claims 6–9?
Featured-snippet answer
Claims 6–9 narrow protection to a specific crystalline form shown by ATR-FTIR band sets and XRPD peak lists measured on specified instruments and under specified tolerances.
ATR-FTIR narrowing (Claims 6–7)
- Claim 6: requires an ATR-FTIR spectrum with absorption bands at 1711, 1637, 1597, 1401 cm−1 (±2 cm−1 for the listed bands).
- Claim 7: adds a much broader fingerprint with bands at 2956(w), 1711(st), 1637(st), 1597(st), 1488(w), 1459(m), 1401(st), 1357(w), 1295(m), 1266(m), 1176(w), 1085(m), 1010(w), 942(w), 907(w), 862(w), 763(st), 742(m), 698(m), 533(st).
Infringement risk increases materially when an accused solid has been manufactured/purified to match the same crystal form. If the accused manufacturer uses different drying conditions, humidity control, or polymorphic control that yields a different ATR-FTIR signature, these dependent claims are positioned as a defense target.
XRPD narrowing (Claims 8–9)
- Claim 8: requires XRPD interlattice plane intervals d (Å) ±0.1 Å with peaks including 21.2(s), 17.0(w), 7.1(s), 5.2(w), 4.7(w), 4.6(w), 4.2(w), 3.5(w), 3.3(w).
- Claim 9: requires an XRPD pattern listed by 2θ (°) ±0.2° including peaks at 4.5, 5.5, 5.6, 9.9, 12.8, 15.7, 17.0, 17.1, 17.2, 18.3, 18.5, 19.8, 21.5, 21.7, 23.2, 23.3, 24.9, 25.3, 27.4, 27.9, 28.0, 30.2.
This creates a practical litigation-style test set. An accused infringer that shows non-matching peak positions (outside tolerance) or a different solvate/polymorph is positioned to avoid dependent-claim infringement, though Claim 1 may still be asserted if the underlying active identity is met.
What crystallographic polymorph is claimed: monoclinic P2i with specific unit cell and Z?
Featured-snippet answer
Claims 10–14 specify a monoclinic unit cell for the hemipentahydrate with P2i space group, defined unit cell parameters (a, b, c, β) and crystallographic content including 12 formula units per unit cell and asymmetric unit content on two-fold positions.
Crystallography limitations
- Claim 10: unit cell content comprises 12 formula units of C48H55N6O8Na3·2.5H2O; monoclinic unit cell.
- Claim 11: the unit cell comprises two asymmetric units on two-fold positions.
- Claim 12: monoclinic unit cell has P2i space group.
- Claim 13: further specifies:
- molecular sum formula C48H55N6O8Na3·2.5H2O
- molecular mass 957.99
- crystal color: colorless
- crystal shape: tabular; hexagonal crystal system; monoclinic space group P21
- Note: the claim text contains a potential internal inconsistency: Claim 12 calls for P2i, Claim 13 states monoclinic space group P21. Both are commonly used for closely related naming conventions, but the excerpt as written is not reconcilable without the full patent specification and figures/tables.
- Claim 14: unit cell asymmetric unit comprises six formula units.
- Claim 15: adds a reduced XRPD 2θ subset requiring peaks at 4.5, 5.6, 12.8, 17.0, 17.2, 19.8, 21.5, 27.4 (±0.2°) on a specified instrument.
How this affects enforcement
The dependent crystallography claims are designed to:
- prevent “design-around-by-identity” via different solid-state forms, while
- preserve enforceability if competitors intentionally reproduce the same salt solvate and crystal habit.
From a business perspective, these are the claims that will dominate any technical product comparison and will be the focus of lab testing in US district court.
How many “claim pathways” exist for infringement: what combination of features triggers liability?
Infringement can be asserted at multiple levels
Even without reading the full specification, the claim dependency indicates at least three enforcement layers:
- Therapeutic layer (Claim 1): heart failure or hypertension + administering therapeutically effective amount + the exact trisodium hemipentahydrate compound.
- Formulation layer (Claim 4): same as Claim 1 plus administration as a pharmaceutical composition.
- Solid-state layer (Claims 5–15): crystalline form plus ATR-FTIR and/or XRPD and/or crystallographic parameters.
This structure creates multiple bargaining chips:
- A generic may try to avoid the specific crystalline form and argue it does not meet dependent claims.
- The patent holder may still pursue Claim 1 if the active ingredient identity includes the hemipentahydrate specification, even if some fingerprint peaks differ.
What generic entry risks exist for the hemipentahydrate: how can a competitor avoid the claims?
Primary design-around strategy
- Use a different hydrate/solvate state (not hemipentahydrate)
- Use a different polymorph of the hemipentahydrate not matching ATR-FTIR and XRPD signatures
- Use a different crystalline form even if the chemical entity is the same
Secondary strategy
- If manufacturing produces a mixture of solid forms, an accused product may attempt to show that the administered solid does not meet the specific dependent claim fingerprint tolerance bands.
Litigation reality
Dependent claims tied to ATR-FTIR/XRPD are sensitive to:
- instrument type and settings
- sample preparation (drying time, humidity equilibration)
- particle size and measurement protocols
- peak picking and baseline correction
Claim language in the excerpt is precise about instrument models for XRPD (“Scintag XDS2000 powder diffractometer”) and uses defined tolerances, which tends to concentrate fact discovery and expert testimony.
What patent estate questions matter: is this a single-form solid-state protection or part of a broader family?
The excerpt is a single US patent number (9,388,134) with both therapeutic and solid-state dependent claims. That pattern is typical of a patent family that includes:
- chemical composition claims (free base/anhydrates/hydrates/polymorphs),
- solid-state characterization claims (ATR-FTIR and XRPD),
- method-of-treatment claims with those solid forms.
However, the broader family members, other US filings, continuation practice, and related patents cannot be enumerated from the claim text alone.
What Orange Book status and FDA regulatory linkage apply to US Patent 9,388,134?
Orange Book listing status and FDA regulatory details are not provided in the excerpt, so they cannot be determined here. Method-of-treatment patents and form-characterization patents commonly appear in different ways in the Orange Book (drug substance and drug product listed patents vs therapeutic method patents), but any mapping would require verified Orange Book records for the specific NDA/ANDA/BLA.
Key Takeaways
- US Patent 9,388,134 is a method-of-treatment patent for heart failure and hypertension using a single defined active ingredient: a trisodium hemipentahydrate crystalline compound with strict structural stereochemistry.
- Dependent claims 5–15 shift infringement from “therapeutic use with correct API” toward “therapeutic use with the correct solid-state identity,” using ATR-FTIR band sets and XRPD peak patterns plus monoclinic crystallographic parameters (including space group naming as written).
- The claim set creates layered enforcement: Claim 1 offers the broadest path; dependent solid-state claims provide targeted leverage when competitors attempt polymorph/hydrate design-arounds.
- The excerpt does not support a quantified, company-by-company competitive litigation landscape, Paragraph IV timing, or Orange Book linkage.
FAQs
-
Can a competitor infringe US 9,388,134 if it sells a different hydrate but keeps the same therapeutic indication?
Dependent claims require the specific crystalline hemipentahydrate identity plus fingerprint features; Claim 1 still requires administration of the specific named hemipentahydrate compound.
-
How do ATR-FTIR dependent claims change the proof burden in infringement trials?
They shift the dispute toward lab-based spectral matching against defined band positions and tolerances, typically dominated by expert testimony and sample preparation protocols.
-
Do XRPD peak tolerances (d ±0.1 Å or 2θ ±0.2°) materially affect design-around feasibility?
Yes. Matching or missing peak positions outside specified tolerances is a central technical lever in claim construction and infringement analysis.
-
What is the practical difference between Claim 8 and Claim 9 XRPD formats?
Claim 8 lists peaks by interlattice spacing d(Å), while Claim 9 lists by 2θ(°). They function as different but overlapping ways to define the diffraction fingerprint.
-
Does the monoclinic unit cell and space group limitation make infringement harder to prove?
Yes for dependent claims. It adds a crystallography identity requirement beyond generic “crystalline form,” increasing reliance on X-ray structural characterization and consistent crystallization conditions.
References
- US Patent 9,388,134 (claim text provided).
More… ↓
⤷ Start Trial
|
